CDT

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 11

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,691,727

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.247-0.405, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 10

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 11,936,119

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.223-0.276, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 9

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,941,319

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.266-0.303, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 8

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 14,331,139

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.279-0.307, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 7

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 14,631,139

F6 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.290-0.307, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 6

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,214,091

F5 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.307-0.371, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 5

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,364,091

F4 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.426-0.452, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 4

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,441,772

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 3

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,477,695

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 2

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,478,695

F1 · price: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F1 · ownership.nature: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 1

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 30,048,454

F1 · price: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F1 · ownership.nature: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001493152-24-023518 · ownership.xml · nonDerivative · entry 1

Farley Chele Chiavacci · CIK 0001908750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,272

F1 · price: The shares have a value in excess of the par value of the company's shares and are fully vested (fully paid and nonassessable) as of June 11, 2024.

SEC source: 0001493152-24-023516 · ownership.xml · nonDerivative · entry 1

Bligh James · CIK 0001990748 · Director · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,272

F1 · price: The shares have a value in excess of the par value of the company's shares and are fully vested (fully paid and nonassessable) as of June 11, 2024.

SEC source: 0001493152-24-019918 · ownership.xml · nonDerivative · entry 1

Sragovicz Adam · CIK 0001727723 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001493152-24-019926 · ownership.xml · derivative · entry 1

McNealey Jennifer Isacoff · CIK 0001588132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2033-11-30

F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.

F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-24-015812 · ownership.xml · derivative · entry 2

Tapolczay David · CIK 0001991789 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,332

Underlying: Common Stock · 200,332 shares

Expires 2027-04-22

F2 · security: Warrants sold in exchange for $0.25 per warrant in private transaction.

F2 · price: Warrants sold in exchange for $0.25 per warrant in private transaction.

SEC source: 0001493152-24-015812 · ownership.xml · derivative · entry 1

Tapolczay David · CIK 0001991789 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,664

Underlying: Common Stock · 400,664 shares

Expires 2027-04-22

F1 · security: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

F1 · price: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

SEC source: 0001493152-24-015813 · ownership.xml · derivative · entry 2

Lewis-Hall Freda C · CIK 0001437909 · Director

Intelmed LLC · CIK 0001994123 · See Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Emerson Hall

Disclosed balance after: 103,397

Underlying: Common Stock · 103,397 shares

Expires 2027-04-22

F1 · security: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

F1 · price: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

F3 · ownership.nature: Such Shares are held by Ms. Lewis-Hall's spouse, Mr. Emerson Hall, Jr. As Mr. Hall's spouse and by virtue of their relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of such shares held by record by Mr. Emerson Hall, Jr. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein.

SEC source: 0001493152-24-015813 · ownership.xml · derivative · entry 1

Lewis-Hall Freda C · CIK 0001437909 · Director

Intelmed LLC · CIK 0001994123 · See Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Intelmed LLC

Disclosed balance after: 400,664

Underlying: Common Stock · 400,664 shares

Expires 2027-04-22

F1 · security: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

F1 · price: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

F2 · ownership.nature: The Shares are held of record by Intelmed LLC ("Intelmed"). Ms. Lewis-Hall is the Managing Director of Intelmed and in such capacity has voting and investment discretion with respect to the Shares held of record by Intelmed. By virtue of this relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of the Shares held of record by Intelmed. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein.

SEC source: 0001493152-24-015814 · ownership.xml · derivative · entry 2

Farley Chele Chiavacci · CIK 0001908750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,332

Underlying: Common Stock · 200,332 shares

Expires 2027-04-22

F2 · security: Warrants purchased in exchange for $0.25 per warrant in private transaction.

F2 · price: Warrants purchased in exchange for $0.25 per warrant in private transaction.

SEC source: 0001493152-24-015814 · ownership.xml · derivative · entry 1

Farley Chele Chiavacci · CIK 0001908750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires 2027-04-22

F1 · security: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

F1 · price: Warrants issued in exchange for one year lock-up of reporting person's common stock of the company, par value $0.0001 per share, and the payment of $0.125 per warrant.

SEC source: 0001493152-23-043747 · ownership.xml · derivative · entry 1

Farley Chele Chiavacci · CIK 0001908750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-11-30

F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.

F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-23-043745 · ownership.xml · derivative · entry 1

Bligh James · CIK 0001990748 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 223,634

Underlying: Common Stock · 223,634 shares

Expires 2033-11-30

F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.

F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 25% on each of the first four anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-23-043748 · ownership.xml · derivative · entry 1

McNealey Jennifer Isacoff · CIK 0001588132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-11-30

F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.

F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-23-043746 · ownership.xml · derivative · entry 1

Charles Faith L. · CIK 0001853985 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-11-30

F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.

F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-23-043750 · ownership.xml · derivative · entry 1

Tapolczay David · CIK 0001991789 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 298,179

Underlying: Common Stock · 298,179 shares

Expires 2033-11-30

F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.

F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 25% on each of the first four anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-23-043749 · ownership.xml · nonDerivative · entry 1

Sragovicz Adam · CIK 0001727723 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,545

F1 · price: The restricted stock units were granted with a vesting schedule of 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-23-044917 · ownership.xml · derivative · entry 1

Lewis-Hall Freda C · CIK 0001437909 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-11-30

F1 · security: Represents Options to purchase common stock, granted under the Company's 2023 Stock Incentive Plan.

F2 · derivative.exercise_date: The stock options were granted with a ten-year term and vest 33.3% on each of the first three anniversaries of the vesting commencement date, which is September 22, 2023.

SEC source: 0001493152-23-033793 · ownership.xml · derivative · entry 2

Farley Chele Chiavacci · CIK 0001908750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Shares · 15,000 shares

Expires 2028-10-22

F2 · derivative.exercise_date: The redeemable warrants become exercisable 30 days after the completion of the business combination contemplated by the Merger Agreement, which occurred on September 22, 2023. Accordingly, the redeemable warrants become exercisable on October 22, 2023 and expire on October 22, 2028.

SEC source: 0001493152-23-033793 · ownership.xml · nonDerivative · entry 1

Farley Chele Chiavacci · CIK 0001908750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Includes 15,000 shares of common stock of the Company and 15,000 redeemable warrants that Murphy Canyon Acquisition Sponsor, LLC transferred to Ms. Farley in consideration for her acting as an independent director of the Company. Such Shares and warrants were transferred to Mr. Farley immediately after the closing of the business combination contemplated by the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 (the "Merger Agreement"), by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc."

F1 · price: Includes 15,000 shares of common stock of the Company and 15,000 redeemable warrants that Murphy Canyon Acquisition Sponsor, LLC transferred to Ms. Farley in consideration for her acting as an independent director of the Company. Such Shares and warrants were transferred to Mr. Farley immediately after the closing of the business combination contemplated by the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 (the "Merger Agreement"), by and among the Company, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly-owned subsidiary of MURF (the "Merger Sub"). As a result of, and upon consummation of the transactions contemplated by, the Merger Agreement, the Company changed its name from "Murphy Canyon Acquisition Corp." to "Conduit Pharmaceuticals Inc."

SEC source: 0001493152-23-033776 · ownership.xml · derivative · entry 4

Heilbron Jack Kendrick · CIK 0001437208 · Former CEO,director&10% owner

Murphy Canyon Acquisition Sponsor, LLC · CIK 0001910050 · Former 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 709,000

Underlying: Common Stock · 709,000 shares

Expires 2028-09-22

F7 · kind: Immediately following the consummation of the IBC, Murphy Canyon Acquisition Sponsor, LLC transferred 45,000 warrants as consideration for their services to three directors, two of whom had resigned upon consummation of the IBC.

F8 · derivative.underlying_shares: Includes 709,000 shares of common stock, which prior to the IBC were shares of Class A common stock.

F3 · ownership.nature: Held by Murphy Canyon Acuqisition Sponsor, LLC (the "Sponsor"). Jack K. Heilbron is the President of the Managing Member of the Sponsor. Mr. Heilbron disclaims any such beneficial ownership except to the extent of his pecuniary interest. Mr. Heilbron resigned as Chief Executive Officer and Chairman of the issuer upon the consummation of the IBC.

SEC source: 0001493152-23-033776 · ownership.xml · derivative · entry 3

Heilbron Jack Kendrick · CIK 0001437208 · Former CEO,director&10% owner

Murphy Canyon Acquisition Sponsor, LLC · CIK 0001910050 · Former 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 754,000

Underlying: Common Stock · 754,000 shares

Expires 2028-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Upon consummation of the issuer's initial business combination (the "IBC"), the issuer's shares of Class B common stock were converted into shares of Class A common stock and the shares of Class A common stock were then reclassified as a single class of common stock.

F6 · derivative.underlying_shares: Includes 754,000 shares of common stock, which prior to the IBC were shares of Class A common stock.

F3 · ownership.nature: Held by Murphy Canyon Acuqisition Sponsor, LLC (the "Sponsor"). Jack K. Heilbron is the President of the Managing Member of the Sponsor. Mr. Heilbron disclaims any such beneficial ownership except to the extent of his pecuniary interest. Mr. Heilbron resigned as Chief Executive Officer and Chairman of the issuer upon the consummation of the IBC.

SEC source: 0001493152-23-033776 · ownership.xml · nonDerivative · entry 2

Heilbron Jack Kendrick · CIK 0001437208 · Former CEO,director&10% owner

Murphy Canyon Acquisition Sponsor, LLC · CIK 0001910050 · Former 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,015,250

F1 · kind: Upon consummation of the issuer's initial business combination (the "IBC"), the issuer's shares of Class B common stock were converted into shares of Class A common stock and the shares of Class A common stock were then reclassified as a single class of common stock.

F4 · kind: Immediately following the consummation of the IBC, Murphy Canyon Acquisition Sponsor, LLC transferred 45,000 shares of common stock as consideration for their services to three directors, two of whom had resigned upon consummation of the IBC.

F5 · balance_after: Includes (i) 3,306,250 shares of common stock due to the conversion of the shares of Class B common stock into shares of Class A common stock and then reclassification into shares of Company common stock and (ii) 709,000 shares of common stock, which prior to the IBC were shares of Class A common stock.

F3 · ownership.nature: Held by Murphy Canyon Acuqisition Sponsor, LLC (the "Sponsor"). Jack K. Heilbron is the President of the Managing Member of the Sponsor. Mr. Heilbron disclaims any such beneficial ownership except to the extent of his pecuniary interest. Mr. Heilbron resigned as Chief Executive Officer and Chairman of the issuer upon the consummation of the IBC.

SEC source: 0001493152-23-033776 · ownership.xml · nonDerivative · entry 1

Heilbron Jack Kendrick · CIK 0001437208 · Former CEO,director&10% owner

Murphy Canyon Acquisition Sponsor, LLC · CIK 0001910050 · Former 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,060,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Upon consummation of the issuer's initial business combination (the "IBC"), the issuer's shares of Class B common stock were converted into shares of Class A common stock and the shares of Class A common stock were then reclassified as a single class of common stock.

F2 · shares: Includes (i) 3,306,250 shares of common stock due to the conversion of the shares of Class B common stock into shares of Class A common stock and then reclassification into shares of Company common stock and (ii) 754,000 shares of common stock, which prior to the IBC were shares of Class A common stock.

F2 · balance_after: Includes (i) 3,306,250 shares of common stock due to the conversion of the shares of Class B common stock into shares of Class A common stock and then reclassification into shares of Company common stock and (ii) 754,000 shares of common stock, which prior to the IBC were shares of Class A common stock.

F3 · ownership.nature: Held by Murphy Canyon Acuqisition Sponsor, LLC (the "Sponsor"). Jack K. Heilbron is the President of the Managing Member of the Sponsor. Mr. Heilbron disclaims any such beneficial ownership except to the extent of his pecuniary interest. Mr. Heilbron resigned as Chief Executive Officer and Chairman of the issuer upon the consummation of the IBC.